Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brainstorm Cell Therapeutics ( (BCLI) ) has issued an update.
On February 9, 2026, Brainstorm Cell Therapeutics Inc. entered into a private placement Securities Purchase Agreement with an accredited investor to sell $1 million of common stock and pre-funded warrants, split into two $500,000 closings. The first closing took place on February 9, 2026, with the second closing scheduled 30 days later, and the deal includes common stock purchase warrants exercisable at $1.00 per share, representing 120% of the shares and pre-funded warrants purchased.
The company agreed to register the resale of the securities within specified timelines, maintain the listing of its common stock and warrant shares on the trading market, and use the net proceeds for working capital purposes. The transaction, executed under Regulation D and Section 4(a)(2) exemptions, underscores Brainstorm’s reliance on structured private financing to support liquidity while managing investor ownership limits and future share overhang through warrant coverage and registration commitments.
The most recent analyst rating on (BCLI) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.
Spark’s Take on BCLI Stock
According to Spark, TipRanks’ AI Analyst, BCLI is a Neutral.
Overall score is held down mainly by weak financial performance (large operating losses, ongoing cash burn, and equity/funding risk). Technicals are also soft with the stock below key longer-term averages. Corporate events add some support via new financing and development progress, but carry dilution/financing risk, and valuation remains constrained by negative earnings and no dividend.
To see Spark’s full report on BCLI stock, click here.
More about Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies, with its common stock listed on a public trading market. The company raises capital through private placements of equity and warrant securities to fund its ongoing operations and working capital needs.
Average Trading Volume: 22,474
Technical Sentiment Signal: Sell
Current Market Cap: $6.46M
Learn more about BCLI stock on TipRanks’ Stock Analysis page.